Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.

If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.

Latest Media Coverage

Wall Street Journal

Pfizer Pivots to Cancer Drugs for Growth

The new lineup is projected to generate $8.3 billion in sales this year, according to EvaluatePharma. For the first time, Pfizer in 2019 expects oncology products to…

Nature Reviews Drug Discovery

Top product forecasts for 2019

Perhaps the most startling thing about the forecasted best-selling drugs in 2019 is the longevity of some of the entrants in the list (Table 1). Humira, once again…

Wall Street Journal

Samsung Faces Resistance From Big Pharma in the U.S.

World-wide sales of biologics totaled $271.8 billion in 2018 and are expected to rise to $290 billion this year, according to EvaluatePharma, a provider of pharmaceutical…

Browse the archive

Wall Street Journal

Pfizer Pivots to Cancer Drugs for Growth

The new lineup is projected to generate $8.3 billion in sales this year, according to EvaluatePharma. For the first time, Pfizer in 2019 expects oncology products to…

Nature Reviews Drug Discovery

Top product forecasts for 2019

Perhaps the most startling thing about the forecasted best-selling drugs in 2019 is the longevity of some of the entrants in the list (Table 1). Humira, once again…

Wall Street Journal

Samsung Faces Resistance From Big Pharma in the U.S.

World-wide sales of biologics totaled $271.8 billion in 2018 and are expected to rise to $290 billion this year, according to EvaluatePharma, a provider of pharmaceutical…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.